ArticleCurrent oncology (Toronto, Ont.)2022

Refractory Splenic Marginal Zone Lymphoma Responsive to Combination Venetoclax and Bortezomib (Velcade) (V

Kyle C Roche et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.